To investigate the impact of wtp53 versus mutp53 on therapy responsiveness we sequenced p53 of 19 melanoma cell samples isolated from 14 patients with known BRAF/NRAS mutation status, and therapeutic record. This evidence concerns the gene NRAS and melanoma.